The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Fatal adverse drug events: the paradox of drug treatment
Abstract
OBJECTIVE: Study patient characteristics, morbidity patterns and drug regimens associated with fatal adverse drug events (FADEs) amongst medical department inpatients. DESIGN: An observational, descriptive study using aggregated medical records, autopsies and pre and postmortem drug analyses. SETTING: A department of internal medicine at a Norwegian county hospital. SUBJECTS: All patients dying in the department over a 2-year period. RESULTS: The incidence of FADEs were 18.2% (133/732). Compared with non-FADE cases, FADE cases were older, used more drugs both on admission and at death, and had higher comorbidity (P < 0.001). Drugs suspected to cause or contribute to fatal outcome were mainly those used for treating chronic pulmonary diseases (terbutaline, theophylline), antithrombotic drugs (aspirin, warfarin, heparines) and drugs for treating coronary heart disease and heart failure (e.g. diuretics, nitrates, angiotensin converting enzymes (ACE) inhibitors, calcium channel blockers). Bronchodilatory drugs, antithrombotic drugs and cardiovascular drugs account for 26, 31 and 30 FADE cases, respectively. Patients dying from gastrointestinal diseases had the highest relative FADE occurrence (42%), cancer patients the lowest occurrence (4%). Serious drug-drug and drug-disease interactions were frequently suspected. Various degrees of inappropriateness in choice of drug, dosage or administration route were seen in 50% of FADE cases. CONCLUSIONS: This study shows a high incidence of FADEs associated with high age, high comorbidity and polypharmacy, and partly to inappropriate drug prescribing or use. Treatments frequently associated with FADEs were bronchodilatory treatment of patients with both chronic obstructive lung disease and coronary heart disease, vasodilatory treatment in patient with endstage heart failure and the combination of several antithrombotic drugs. A systematic strategy is needed to avoid unnecessary adverse drug events (ADEs).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention
Bates, D. W. (1995) · JAMA · doi:10.1001/jama.1995.03530010043033 · Cited by 2,127
Relationship between medication errors and adverse drug events
Bates, D. W., Boyle, D. L., Vliet, M. B. V., Schneider, J., & Leape, L. (1995) · Journal of General Internal Medicine · doi:10.1007/bf02600255 · Cited by 981
Cited by
Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis
Ranpura, V., Hapani, S., & Wu, S. (2011) · JAMA · doi:10.1001/jama.2011.51 · Cited by 428
Thomsen, L. A., Winterstein, A. G., S⊘ndergaard, B., Haugb⊘lle, L. S., & Melander, A. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h658 · Cited by 393
Medication Withdrawal Trials in People Aged 65 Years and Older: A Systematic Review
Iyer, S., Naganathan, V., McLachlan, A. J., & Le Couteur, D. G. (2008) · Drugs & Aging · doi:10.2165/0002512-200825120-00004 · Cited by 339
Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
Riechelmann, R. P., Tannock, I. F., Wang, L., Saad, E. D., Taback, N. A., & Krzyzanowska, M. K. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk130 · Cited by 328
Klarin, I., Wimo, A., & Fastbom, J. (2005) · Drugs & Aging · doi:10.2165/00002512-200522010-00005 · Cited by 300
Metadata
- Authors
- Buajordet, I., Ebbesen, J., Erikssen, J., Brors, O., & Hilberg, T.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2001-10-13
- Volume
- 250
- Issue
- 4
- Pages
- 327-341
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2002948677
- Cited by
- 219
- References
- 2
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatal adverse drug events: the paradox of drug treatment. https://app.cochat.ai/papers/10.1046/j.1365-2796.2001.00892.x
- The paper
- Buajordet, I., Ebbesen, J., Erikssen, J., Brors, O., & Hilberg, T. (2001). Fatal adverse drug events: the paradox of drug treatment. Journal of Internal Medicine. https://doi.org/10.1046/j.1365-2796.2001.00892.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.